Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Pancreatic Ductal
/ pathology
Chemokine CCL4
Cytokines
/ therapeutic use
Fluorouracil
Humans
Interleukin 1 Receptor Antagonist Protein
/ therapeutic use
Interleukin-18
Interleukin-7
Irinotecan
Leucovorin
Oxaliplatin
Pancreatic Neoplasms
/ pathology
Pancreatic Neoplasms
IL-1RA
biomarker
cytokine
pancreatic cancer
treatment response
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
03
2022
accepted:
26
07
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
Biomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of circulating cytokines with FOLFIRINOX response and with overall survival (OS). Serum samples were collected before start and after the first cycle of FOLFIRINOX from patients with PDAC ( Patients with high serum IL-1RA concentrations after one cycle of chemotherapy were less likely to have tumor progression during FOLFIRINOX (OR 0.25, Circulating IL-1RA, IL-7, IL-18, and MIP-1β concentrations are biomarkers associated with FOLFIRINOX response in PDAC patients, suggesting an important role for specific immune cells in chemotherapy response and PDAC progression. Cytokine-based treatment might improve patient outcome and should be evaluated in future studies.
Sections du résumé
Background
Biomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of circulating cytokines with FOLFIRINOX response and with overall survival (OS).
Methods
Serum samples were collected before start and after the first cycle of FOLFIRINOX from patients with PDAC (
Results
Patients with high serum IL-1RA concentrations after one cycle of chemotherapy were less likely to have tumor progression during FOLFIRINOX (OR 0.25,
Conclusions
Circulating IL-1RA, IL-7, IL-18, and MIP-1β concentrations are biomarkers associated with FOLFIRINOX response in PDAC patients, suggesting an important role for specific immune cells in chemotherapy response and PDAC progression. Cytokine-based treatment might improve patient outcome and should be evaluated in future studies.
Identifiants
pubmed: 36091056
doi: 10.3389/fimmu.2022.898498
pmc: PMC9454314
doi:
Substances chimiques
Chemokine CCL4
0
Cytokines
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-18
0
Interleukin-7
0
folfirinox
0
Oxaliplatin
04ZR38536J
Irinotecan
7673326042
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
898498Informations de copyright
Copyright © 2022 van der Sijde, Dik, Mustafa, Vietsch, Besselink, Debets, Koerkamp, Haberkorn, Homs, Janssen, Luelmo, Mekenkamp, Oostvogels, Smits-te Nijenhuis, Wilmink, van Eijck and the Dutch Pancreatic Cancer Group.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Immunol. 2008 Jan;8(1):59-73
pubmed: 18097448
Br J Cancer. 2021 Feb;124(3):581-586
pubmed: 33100327
PLoS One. 2016 May 12;11(5):e0154016
pubmed: 27170998
Br J Cancer. 2021 Jun;124(12):1941-1948
pubmed: 33772154
BMC Cancer. 2021 Mar 23;21(1):300
pubmed: 33757440
Nature. 2012 Nov 15;491(7424):399-405
pubmed: 23103869
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764482
J Immunol. 1996 Feb 15;156(4):1594-600
pubmed: 8568265
Science. 2004 Oct 22;306(5696):704-8
pubmed: 15499023
Medicine (Baltimore). 2021 Jan 22;100(3):e24068
pubmed: 33546009
Cancer Immunol Res. 2014 Sep;2(9):823-30
pubmed: 25187272
Dose Response. 2020 Aug 03;18(3):1559325820942065
pubmed: 32821253
J Clin Oncol. 2015 Nov 20;33(33):3968-71
pubmed: 26392104
J Infect Chemother. 2017 Apr;23(4):196-200
pubmed: 28087305
J Clin Med. 2018 Jan 04;7(1):
pubmed: 29300345
J Immunother. 2009 Nov-Dec;32(9):920-31
pubmed: 19816189
Ann Surg. 2019 Jul;270(1):139-146
pubmed: 29334554
Pancreas. 2012 Oct;41(7):1001-7
pubmed: 22722257
Clin Cancer Res. 2020 Apr 15;26(8):1997-2010
pubmed: 31964786
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Cancers (Basel). 2019 Jan 15;11(1):
pubmed: 30650521
Oncoimmunology. 2017 Apr 28;6(9):e1322242
pubmed: 28932629
Mol Cancer. 2017 Sep 19;16(1):153
pubmed: 28927416
Int J Oncol. 2009 Jun;34(6):1701-15
pubmed: 19424589
Exp Ther Med. 2012 Jul;4(1):70-78
pubmed: 23060925
Neth J Med. 2020 Sep;78(5):220-231
pubmed: 33093245
J Immunother Cancer. 2019 Jun 8;7(1):149
pubmed: 31176366
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
PLoS One. 2019 Oct 17;14(10):e0223897
pubmed: 31622413
Clin Cancer Res. 2016 Mar 15;22(6):1432-44
pubmed: 26500238
Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6
pubmed: 15203102
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Int J Cancer. 2020 Feb 1;146(3):692-698
pubmed: 30924141
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Br J Cancer. 2016 Mar 29;114(7):737-43
pubmed: 27022826
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Tumour Biol. 2014 Nov;35(11):11467-72
pubmed: 25123265
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Cancer Treat Rev. 2017 Jul;58:1-13
pubmed: 28602879
Gut. 2011 Jun;60(6):861-8
pubmed: 20966025
Front Immunol. 2013 Oct 08;4:289
pubmed: 24115947
Br J Cancer. 2013 May 28;108(10):2063-9
pubmed: 23591198
Clin Cancer Res. 2016 May 15;22(10):2565-74
pubmed: 26719427
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Cancer Res. 2020 Mar 1;80(5):1088-1101
pubmed: 31915130